Technology Overview:
Staphylococcus aureus is a bacterial pathogen responsible for significant morbidity, mortality, and excess healthcare cost worldwide. Treatment of S. aureus infection has become difficult due to the prevalence of antibiotic resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA).
The inventors have identified novel vaccine candidates which elicit robust humoral responses and effectively reduced the acquisition and colonization of S. aureus, including MRSA in vivo. A preventive vaccine or treatment therapy based on this technology represents a major clinical advance and would address a multibillion dollar market opportunity.
Intellectual Property:
Pending worldwide and additional US rights
Reference Media:
Lijek, R. S. et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13823-8
Case ID:
W5484-tpNCD
Web Published:
6/1/2017
Patent Information:
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |